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A B S T R A C T
Background
There is some evidence for the benefits of leukodepletion in patients undergoing coronary artery surgery. Its effectiveness in higher risk
patients, such as those undergoing heart valve surgery, particularly in terms of overall clinical outcomes, is currently unclear.
Objectives
Toassess the beneficial andharmful effects of leukodepletionon clinical, patient-reported and economic outcomes in patients undergoing
heart valve surgery.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 3 of 12) in The Cochrane Library, the NHS
Economic Evaluations Database (1960 to April 2013), MEDLINE Ovid (1946 to April week 2 2013), EMBASE Ovid (1947 to Week
15 2013), CINAHL (1982 to April 2013) and Web of Science (1970 to 17 April 2013) on 19 April 2013. We also searched the World
Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), the US National Institutes of Health (NIH)
clinical trials database and the International Standard Randomised Controlled Trial Number Register (ISRCTN) in April 2013 for
ongoing studies. No language or time period restrictions were applied. We examined the reference lists of all included randomised
controlled trials and contacted authors of identified trials. We searched the ’grey’ literature at OpenGrey and handsearched relevant
conference proceedings.
Selection criteria
Randomised controlled trials comparing a leukocyte-depleting arterial line filter with a standard arterial line filter, on the arterial outflow
of the heart-lung bypass circuit, in elective patients undergoing heart valve surgery.
Data collection and analysis
Data were collected on the study characteristics, three primary outcomes (1. post-operative in-hospital all-cause mortality within three
months, 2. post-operative all-cause mortality excluding inpatient mortality < 30 days, 3. length of stay in hospital, 4. adverse events
and serious adverse events) and seven secondary outcomes (1. tubular or glomerular kidney injury, 2. validated health-related quality
of life scales, 3. validated renal injury scales, 4. use of continuous veno-venous haemo-filtration, 5. length of stay in intensive care, 6.
costs of care). Data were extracted by one author and verified by a second author. Insufficient data were available to perform a meta-
analysis or sensitivity analysis.
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Main results
Eight studies were eligible for inclusion in the review but data on prespecified review outcomes were available from only one, modestly
powered (24 participants) study (Hurst 1997). There were no differences between a leuko-depleting versus standard filter in length
of stay in the intensive care unit (ICU) (mean difference (MD) 0.80 days; 95% confidence interval (CI) -0.24 to 1.84) or length of
hospital stay (MD 0.20 days; 95% CI -1.78 to 2.18).
Authors’ conclusions
There are currently insufficient good quality trials with valve surgery patients to inform recommendations for changes in clinical practice.
A future National Institute for Health Research (NIHR)-funded feasibility study (recruiting mid-year 2013) comparing leukodepletion
with a standard arterial line filter in patients undergoing elective heart valve surgery (the ROLO trial) will be the largest study to date
and will make a significant contribution to future updates of this review.
P L A I N L A N G U A G E S U M M A R Y
Leukodepletion for patients undergoing heart valve surgery
Patients undergoing heart valve surgery are at a higher risk of developing complications after surgery, such as damage to the kidneys,
compared with patients who undergo coronary artery surgery alone. The injury to organs is associated with an increased risk of death,
longer stay in hospital and higher costs of care. A systemic inflammatory response is thought to be responsible for this effect. One
possible mechanism for this response is activation of white blood cells (leucocytes) as they come into contact with the heart and lung
bypass machine during surgery. In an attempt to avoid this inflammation response, special filters have been developed that capture the
leucocytes while patients are on the bypass machine.
The authors of this review evaluated whether these filters were safe to use and effective in reducing the risk of death, length of stay in
intensive care and hospital, impairment of kidney functioning, costs of care, and improving quality of life in patients undergoing heart
valve surgery. We searched the literature and found eight studies, comprising at least 185 patients, that met our inclusion criteria for the
review. However, only one study with 24 participants could provide data on any of our review outcomes. The study showed that length
of stay in intensive care and length of stay in hospital were not different between patients who had surgery with the leukodepletion
filter compared to a standard filter. None of the studies reported on death rates or five of the seven secondary outcomes that the review
aimed to evaluate.
The authors concluded that there were not enough good quality trials in patients undergoing valve surgery to determine whether
leukodepletion works. More good quality research studies with relevant outcome measures are required. A forthcoming study will help
to clarify the findings in a future update of the review.
B A C K G R O U N D
Description of the condition
Diseases of the heart valves can dramatically worsen quality of life
and cause premature death if left untreated. Although the under-
lying causes of heart valve disease vary considerably between de-
veloped and developing countries, the burden of disease in West-
ern economies is substantial, partly due to an ageing popula-
tion and the accompanying increase in degenerative valve diseases
(Soler-Soler 2000; Vahanian 2007). Prevalence of valvular heart
disease in the general US population is estimated at 2.5%, with
age-related increases rising to 13% in people over 75 years (Nkomo
2006). In the period 2000 to 2010, the proportion of valve surg-
eries in the United States rose from 16% to 22% of all cardiac
surgeries (Iung 2011). Despite recent innovations, the gold stan-
dard treatment remains open heart surgery to repair or replace the
damaged valves (Dunning 2011; Iung 2003). Positive outcomes
of such surgery include increased life expectancy and improved
quality of life (Brown 2009; Vahanian 2007). However, there are
intrinsic risks associated with heart valve operations which cannot
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be avoided (Grayson 2003).
Patients undergoing heart valve surgery are at more than twice
the risk of developing post-operative end organ injury, such as
acute kidney injury (AKI), the most prevalent adverse event, com-
pared with patients who undergo coronary artery surgery alone
(Grayson 2003). The crude incidence of acute renal failure for
isolated coronary artery bypass grafting, isolated valve operation,
and a valve with coronary artery bypass grafting operation was
1.9%, 4.4%, and 7.5%, respectively (P < 0.001) when estimated
over a four-year period in the Liverpool Cardiothoracic Centre
(Grayson 2003). Although the risk for acute kidney injury (AKI)
is undoubtedly influenced by the presence of established patient-
related (increasing age, diabetes), cardiac (left ventricular ejection
fraction < 40%) and co-morbidity (pre-existing renal dysfunction)
factors, valvular heart surgery per se is associated with an increased
incidence of this complication due to the more prolonged heart-
lung bypass time and haemoglobinuria arising from haemolysis
induced by extended cardiotomy suction. The international Kid-
ney Disease: Improving Global Outcomes (KDIGO) guidelines
define AKI when one of the following criteria is met: serum cre-
atinine rises by ≥ 26 µmol/L within 48 hours or serum creati-
nine rises ≥ 1.5 fold from the reference value (which is known or
presumed to have occurred within one week) or urine output is <
0.5 ml/kg/hr for > 6 consecutive hours (KDIGO 2012). It is esti-
mated that around 8% of patients undergoing heart surgery expe-
rience post-operative renal dysfunction and 1.5% require dialysis
(Mangano 1998). Post-operative length of stay in the intensive
care unit (ICU) may be twice as long for patients with renal dys-
function (five times longer for dialysis) and the mortality rate is
also significantly higher at 27% for patients with post-operative
renal dysfunction compared to 0.9% for those without (Mangano
1998). Even mild AKI is associated with a twofold increase in
mortality rate, longer stay in ICU (x 1.6) and increased costs of
care (x 1.6), with risk and costs escalating with severity of kidney
injury (Dasta 2008). This same mechanism may lead to the fail-
ure of other organs (multi-organ dysfunction), which is a major
cause of chronic ill-health and death (Thadhani 1996). Avoiding
cardiac surgery associated AKI is therefore crucial due to the asso-
ciated higher mortality rates, increased length of stay in ICU and
elevated costs (Brown 2010; Dasta 2008).
Description of the intervention
A special device, called the leukodepletion (LG6) filter, has been
developed that can successfully remove activated leukocytes (white
blood cells) during the heart-lung bypass process which is manda-
tory for all heart valve surgery. These specially engineered filters
combine a depth element with a screening component in order to
trap activated leucocytes. Early studies demonstrated a reduction
in inflammation and lung injury with the use of the filter during
blood transfusions (Bando 1990; Bando 1991). Its effectiveness in
removing the activated portion of leukocytes in circulating blood
has been validated (Alexiou 2006; Gourlay 1992), though use of
the filter is associated with an additional cost of approximately
GBP80 each. It was first used during heart and lung bypass surgery
during the early 1990s (Palanzo 1993; Schueler 1992) and since
then leukocyte filters have been used at different sites in the heart-
lung bypass circuit showing good performance and patient safety
(Gu 1996; Gu 1999; Sawa 1994). Its effectiveness in ameliorat-
ing AKI, as defined by biomarkers, had been validated in low-risk
coronary artery bypass patients (Tang 2002). The mode of action
is to reduce the systemic inflammatory response (SIR) associated
with use of the extra-corporeal circuit during heart-lung bypass.
Peri-operative riskmay bemediated by leucocyte activation, which
may form the basis of SIR. The potential link between leucocyte
activation and SIR is supported by evidence of a genetic basis for
individual variation in the magnitude of SIR associated with car-
diopulmonary bypass surgery (Jouan 2012). There is no evidence
supporting a link between leucocyte activation and pre-existing
co-morbidities in the cardiac surgical population.
How the intervention might work
A standard arterial line filter removes microemboli (gas, fat, ag-
gregates) from blood passing through the cardiopulmonary bypass
circuit. In addition, the leukodepletion filter has been proven to
remove activated circulating leukocytes (Gourlay 1992; Gourlay
1992b; Gu 1999; Morris 2001; Thurlow 1996). When a patient’s
blood comes into contact with the artificial components of the
heart and lung bypass circuit, the leucocytes become activated,
which may lead to a SIR and the elevated risk of multi-organ
dysfunction and death (Allen 1997; Butler 1993; Kirklin 1991;
Westaby 1987). The role of activated leukocytes in the develop-
ment of post-operative complications is well documented (Hunt
2007). Laboratory evidence for kidney protection (renoprotec-
tion) using the leukodepletion filter has been demonstrated with
low-risk patients undergoing coronary artery surgery (Tang 2002).
However, this study did not demonstrate clinical evidence of a
reduction in kidney injury and the authors suggested that benefits
may be more discernible in patients with moderate to high risk of
developing kidney injury, for example, patients undergoing heart
valve surgery. This cohort are at a higher risk of end-organ fail-
ure because they face additional challenges, such as increased time
spent on the heart-lung machine and increased blood spillage and
salvage. The sequelae of these additional challenges include an in-
crease in leukocyte activation leading to a greater risk of morbid-
ity and mortality. Reducing the number of activated leukocytes
using a leukodepletion filter may reduce the risk of organ injury
(Tang 2002). Leukodepletion may therefore reduce post-surgical
mortality and length of stay, and improve long-term quality of life
(Antunes 2004; Conlon 1999). To our knowledge there are no
known side effects or harms associated with use of the leukode-
pletion filter compared to a standard arterial line filter.
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Why it is important to do this review
There is some evidence for the benefits of leukodepletion in pa-
tients undergoing coronary artery surgery (Bolcal 2007) but its ef-
fectiveness in higher-risk patients, such as those undergoing heart
valve surgery, has not previously been reviewed. Evidence for the
benefit of leukodepletion in terms of overall clinical outcomes in
heart surgery is currently unclear (Efstathiou 2003; Fabbri 2001;
Gott 2001; Sutton 2005). Although leukodepletion during car-
diopulmonary bypass has contributed to improved heart and lung
function, this has not translated into better overall clinical out-
comes (Efstathiou 2003). Thismay be partly due to studies on low-
risk patients, who are not expected to have frequent complications
(Tang 2002). The impact of heart surgery from the patient’s per-
spective is an important considerationwhen evaluating the efficacy
of an intervention. The subjective measurement of health-related
quality of life (HRQoL) is an established outcomemeasure follow-
ing cardiac surgery (Bennet 2002; Blumenthal 1994; Caine 1991;
Papadopoulou 2009) and is able to predict post-surgical functional
status (Falcoz 2003) and level of disability (Juergens 2010). In
addition, post-operative HRQoL can be predicted by the severity
of pre-operative heart failure and type of valve surgery (Baberg
2004; Falcoz 2003; Taillefer 2005). Pre-operative HRQoL scores
have recently been confirmed as independent predictors of post-
operative mortality and myocardial infarction, leading to a call for
their inclusion in the standard set of assessments (Pedersen 2010).
Evidence for the impact of leukodepletion on a patient’s lifestyle
and well-being has not previously been collated. A leukodeple-
tion filter is relatively inexpensive compared to the cost of renal
replacement therapy and prolonged intensive care, but few studies
have evaluated cost savings. However, in a small US study Palanzo
and colleagues reported potential savings in post-operative hos-
pital costs of USD 2892 per patient (Palanzo 1993). Prevention
of end-organ injury during valvular surgery could represent sub-
stantial cost savings (Mangano 1998) and it is therefore important
to review the potential reduction in costs of care associated with
use of the leukodepletion filter. It was the aim of this review to
comprehensively evaluate the impact of leukodepletion on clini-
cal, economic and health-related quality of life outcomes in pa-
tients undergoing heart valve surgery.
O B J E C T I V E S
To assess the beneficial and harmful effects of leukodepletion on
clinical, patient-reported and economic outcomes in patients un-
dergoing heart valve surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
Included
Adult (≥ 18 years) patients requiring surgical intervention for
heart valve disease, including single or multiple valves, first time
or redo procedures. Trials considering concomitant procedures,
such as coronary artery bypass graft, ascending aortic or root re-
placement, and ablation for atrial fibrillation, were considered for
inclusion.
Excluded
Patients for whom the principal risk of peri-operative end-organ
injury was related to factors other than heart valve surgery were
excluded from the review, including patients with known pre-
existing renal disease, impaired left ventricular function (EF <
40%), diabetes or requiring perioperative nephrotoxicmedication,
or deep hypothermic circulatory arrest.
Types of interventions
Studies that compared a leukocyte-depleting arterial line filter
compared to a standard arterial line filter at any site in the heart-
lung bypass circuit.
Types of outcome measures
Primary outcomes
1. Post-operative in-hospital all-cause mortality (within three
months)
2. Post-operative all-cause mortality excluding inpatient
mortality < 30 days
3. Length of stay in hospital
4. Adverse events: adverse events or serious adverse events
(ICH-GCP 1997)
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Secondary outcomes
1. All forms of acute kidney injury (AKI), as defined by
KDIGO 2012
2. Validated health-related quality of life scales (HRQoL)
3. Validated renal injury scale, e.g. Acute Kidney Injury
Network (AKIN) (Mehta 2007) or Risk, Injury, and Failure; and
Loss, and End-stage kidney disease (RIFLE) (Bellomo 2004)
criteria
4. Use of continuous veno-venous haemo-filtration (CVVH)
5. Length of stay in intensive care
6. Costs of care; cost-benefit, cost-effectiveness
Search methods for identification of studies
The search strategies are included in Appendix 1. The search cri-
teria and overall strategy for identification of studies for this re-
view is in accordance with the Cochrane Handbook for Systematic
Reviews of Interventions (Lefebvre 2011).
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (2013, Issue 3 of 12) in The Cochrane Library, the
National Health Service (NHS) Economic Evaluations Database
(1960 to April 2013), MEDLINE Ovid (1946 to April week 2
2013), EMBASEOvid (1947 toWeek 15 2013), CINAHL (1982
to April 2013) and Web of Science (1970 to 17 April 2013) on
19 April 2013.
We also searched the World Health Organization (WHO) In-
ternational Clinical Trials Registry Platform (ICTRP) (http://
apps.who.int/trialsearch/), the US National Institutes of Health
(NIH) clinical trials database (http://www.clinicaltrials.gov/) and
the International Standard Randomised Controlled Trial Number
Register (ISRCTN) (http://www.controlled-trials.com/isrctn/) in
April 2013 for ongoing studies. No language or time period re-
strictions were applied.
The Cochrane sensitivity-maximising RCT filter was applied to
MEDLINE and adaptations of it were applied to EMBASE and
Web of Science (Lefebvre 2011).
We also conducted a wider search for reports of adverse events
(Loke 2011) in a broad range of studies, for example quasi-exper-
imental, cohort studies, etc., in MEDLINE Ovid (1946 to April
week 3 2013) and EMBASE Ovid (1947 to 29 April 2013) on 30
April 2013 (Appendix 2).
Searching other resources
We examined the reference lists of all included RCTs and iden-
tified reviews for additional trials. We contacted authors of iden-
tified trials and authorities in the field in order to locate other
published and unpublished studies. We searched the ’grey’ liter-
ature at OpenGrey (http://www.opengrey.eu/) and handsearched
the following conference proceedings from 2008 to April 2013:
American Heart Association, European Society of Cardiology, In-
ternational Conference on Heart & Brain, International Meeting
of Intensive Cardiac Care, Pan American Heart Failure Congress
and South American Congress of Cardiology.
Data collection and analysis
Selection of studies
The titles and abstracts of all retrieved trials were independently
assessed for relevance by two authors (SS and EK). Using the full
text, each potentially eligible study was evaluated for inclusion in
the review by the two authors. Disagreements about eligibility and
inclusion were resolved following discussion with the third author
(AT).
Data extraction and management
We used a data collection form based on the defined outcome
measures. Data for the comparison of leukodepletion filter versus
standard filter were extracted from included studies by one au-
thor (SS) and verified by a second author (EK). Where data were
missing or further information was required we wrote to the study
authors requesting the required information. Information on the
design, participants, intervention, outcomes, methods, results and
study withdrawals were recorded.
Two authors (SS and EK) evaluated the methodological quality
of the studies. Disagreements and clarification on published data
were resolved by consensus. Where no consensus was reached, the
third author (AT) acted as mediator.
Assessment of risk of bias in included studies
We assessed the risk of bias for all included studies according to rec-
ommendations outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) for the following items.
1. Allocation sequence generation.
2. Concealment of allocation.
3. Blinding of participants and investigators.
4. Incomplete outcome data.
5. Selective outcome reporting.
Each potential source of bias was graded as high, low or unclear.
Other sources of bias were noted.
Measures of treatment effect
Analyses were performed using Review Manager 5.2. For contin-
uous data the treatment effect was estimated using a weighted
mean difference (WMD) with a fixed-effect model. Dichotomous
variables would have been compared using risk ratios (RR) with
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a fixed-effect model, but no data were available for analysis. If we
had included trials with more than two arms and the variance of
the difference between the leukodepletion filter and standard filter
was not reported, we planned to calculate this from the variances
of all the trial arms, but no such studies were included. If studies
had only reported data for differences between treatment groups
as opposed to mean effects for each group, we planned to analyse
the data using the generic inverse variance (GIV) function with a
fixed-effect model, but no such studies were included.
Unit of analysis issues
Where cross-over RCTs were identified for inclusion we planned
to use data from only the first part of the study in order to min-
imise potential bias from carry-over effects, though no cross-over
studies were identified for inclusion in the review.Where trials had
more than two arms and the variance of the difference between
the leukodepletion filter and standard filter was not reported, we
planned to calculate this from the variances of all the trial arms.
Where only data for differences between treatment groups were
presented, as opposed to the mean effects for each group, we
planned to analyse the data using the generic inverse variance
(GIV) function with a fixed-effect model.
Dealing with missing data
We used an intention-to-treat approach and missing data were
not imputed. Where applicable, all authors were contacted for
missing data. If there had been enough trials, we had planned to
use sensitivity analyses to determine the resistance of our results
to the effects of missing data.
Assessment of heterogeneity
We planned to test for heterogeneity in Review Manager 5.1 us-
ing the I2 statistic, where an I2 greater than 40% is considered
meaningful (Higgins 2011). If there had been enough trials we
would have explored heterogeneity by checking data integrity and
carrying out subgroup analyses.
Assessment of reporting biases
Had there been a sufficient number of studies, we planned to ex-
plore reporting biases and the effects of small studies using Egger’s
method (Egger 1997) to test for asymmetry in funnel plots.
Data synthesis
If there had been sufficient data, we planned to examine the com-
bined effects of interventions by pooling data using meta-analysis.
We planned to use fixed-effect models a priori, comparing the re-
sults with a random-effects model where substantial heterogeneity
was indicated.
Subgroup analysis and investigation of heterogeneity
Where comparison group sample sizes permitted, we planned to
conduct subgroup analyses for the following variables: heart dis-
ease severity (for example using the New York Heart Association
classification), follow-up duration (≤ one month, > one month),
age and sex.
Sensitivity analysis
Where substantial heterogeneity was present we planned to exam-
ine robustness of the results by comparing fixed-effect to random-
effects models. In addition, we planned to test reliability of the
meta-analyses by repeating the tests with alternate decision path-
ways including risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies
Results of the search
A total of 4300 citations with abstracts were screened for rele-
vance, of which 32 studies were identified as potentially eligi-
ble for inclusion. Full text papers were obtained for these stud-
ies and 19 were excluded from the review for the reasons listed
in the table Characteristics of excluded studies. Five studies re-
quired clarification on type of surgery, nature of the control group
or study design; we have written to the authors requesting fur-
ther information. Details are listed in the table Characteristics of
studies awaiting classification. Eight RCTs with 185 adult valve
surgery patients undergoing cardiopulmonary bypass with either
a leukodepletion or standard arterial line filter were eligible for in-
clusion in the review. One of these included patients undergoing
either coronary artery bypass graft (CABG) or valve surgery, but
did not state the number of patients in the subgroup undergoing
valve surgery (Palanzo 1993). Details of the studies are shown in
the table Characteristics of included studies and the study flow
diagram is provided in Figure 1. Of the eight studies eligible for
inclusion in the review only two included valve surgery patients
alone (Hachida 1995; Hurst 1997). Two studies included CABG,
congenital defect or valve surgery patients (Chen 2002; Leal-Noval
2005) and the remaining four studies included CABG or valve,
or both, surgery patients (Chen 2004; Efstathiou 2003a; Palanzo
1993a; Soo 2010). We contacted all authors of the six mixed sur-
gical population studies that included valve patients requesting
information on this subgroup of patients alone, but no usable data
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were available. Of the two studies that included valve surgery pa-
tients alone, Hachida did not measure any of the outcomes spec-
ified in our review (Hachida 1995). Only Hurst (Hurst 1997)
measured outcomes relevant to our review and details are reported
below.
Figure 1. Study flow diagram.
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Included studies
Study design
Of the eight studies eligible for inclusion in the review, we were
only able to obtain data on valve surgery patients for outcomes
specified in the review from one study (Hurst 1997). This was a
single centre RCT with investigators blinded to the intervention.
Blinding of patients was not specifically reported but in our view
it was highly unlikely that patients would know to which filter
group they had been assigned without being specifically informed.
Randomisation and allocation schedules were not reported in de-
tail.
Sample size
The study included 24 participants, 11 randomised to a leuko-
depleting arterial line filter and 13 to a standard arterial line filter.
Participants
Patients were on average 62 years old (46% male) with a mean
body mass index of 26.4. All patients electively received open heart
valve surgery: six mitral valve, 12 aortic valve and six both. Nine
patients had a left ventricular ejection fraction (LVEF) < 50%
and we contacted the authors to determine whether any of these
patients had an LVEF < 40%, that is it would meet our exclusion
criteria. Unfortunately these data were not available and we elected
to include all of the study participants.
Interventions
The study compared a Pall LG6 arterial line leukodepletion filter
with a Pall Autovent SP filter (standard arterial).
Outcomes
Mean cardiopulmonary bypass time was 160 minutes with a mean
time of 113 minutes to cross-clamp release. Significantly more pa-
tients in the standard filter group reported cough prior to surgery
compared to the leukodepletion group (P < 0.05). There were no
other significant differences between the groups prior to surgery.
The study measured haemodynamics, white blood cell counts,
platelet counts, cardiac index, blood gases, weight, chest x-rays,
fluid balance, forced expiratory volume in one second (FEV1),
forced vital capacity (FVC), echocardiography, fractional shorten-
ing, ejection fraction, wall motion abnormalities, atelectasis and
myocardial infarctions. The only outcomes measured in the study
that matched the protocol criteria were: total length of hospital-
isation and length of ICU stay, therefore these were included in
the review analyses.
Excluded studies
Nineteen studies did not meet the review inclusion criteria. Two
were in vitro studies (Soo 2008; Soo 2009), eight studies did not
use an arterial line leukodepletion filter (Bilgin 2002; Dell’Amore
2010; El-Tahan 2009; Gu 1999a; Pala 1995; Smit 1999; van de
Watering 1996; Zhang 2010), six studies did not include valve
surgery patients (Hamada 2001; Johnson 1995; Komai 1998; Lust
1996;Matheis 2001b; Scholz 2002), two studies used a compound
intervention that included a leukodepletion filter amongst other
intervention components (Gott 1998; Onorati 2011). One study
met our review exclusion criteria with an ejection fraction < 40%,
reporting an average population ejection fraction below this crite-
rion (Karaiskos 2004).
Risk of bias in included studies
Figure 2 shows the authors’ (SS and EK) judgements on risk of
bias of the included studies. Risk of bias in the one study that
contributed data to the review was generally unclear, with the
exception of personnel blinding, which was assessed as low risk of
bias (Hurst 1997).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The randomisation sequence generation was clearly described in
only one of the included studies (Leal-Noval 2005) and study
allocation was clearly described in only two studies (Leal-Noval
2005; Soo 2010).
Blinding
Only two studies blinded study personnel (Hurst 1997; Soo2010),
with unclear blinding of personnel in the other studies. No stud-
ies specifically described blinding of participants. Blinding of out-
come assessment to minimise detection bias was not reported in
any of the eight studies.
Incomplete outcome data
Follow-up of all planned outcomes was clearly described in three
of the studies (Chen 2002; Chen 2004; Soo 2010), unclear in four
studies (Efstathiou 2003a; Hachida 1995; Hurst 1997; Palanzo
1993a), and one study had a high risk of attrition bias (Leal-Noval
2005).
Selective reporting
Reporting bias was unclear in three studies (Efstathiou 2003a;
Hurst 1997; Leal-Noval 2005) but all planned outcomes were
clearly reported in the other five studies.
Effects of interventions
Primary outcomes
Post-operative in-hospital all-cause mortality within three months
of discharge and post-operative all-cause mortality excluding < 30
day inpatient mortality were not measured in any of the included
studies.
Data on length of hospital stay were available from only one study.
No differences were indicated between the two groups (MD 0.20
days; 95% CI -1.78 to 2.18) (Analysis 1.1).
Adverse events were not reported in Hurst 1997. Of the other
studies meeting our inclusion criteria, adverse events were mea-
sured in two studies (Efstathiou 2003a; Leal-Noval 2005) and
serum creatinine ratio (a marker of renal function) was measured
in one study (Soo 2010), but these data were not available solely
for patients undergoing valve surgery.
Secondary outcomes
The only secondary outcome data available for analysis for valve
surgery patients were for length of stay in ICU. There were no
differences between the groups (MD 0.80 days; 95% CI -0.24 to
1.84) (Analysis 1.2). This outcome was measured in four other
studies (Efstathiou 2003a; Leal-Noval 2005; Palanzo 1993a; Soo
2010) but data were not available for valve surgery patients alone.
D I S C U S S I O N
Summary of main results
Eight studies were eligible for inclusion in the review but data
on prespecified review outcomes were only available from one
modestly powered study (24 participants) (Hurst 1997). There
were no differences in length of stay in ICU (MD 0.80 days; 95%
CI -0.24 to 1.84) or length of hospital stay (MD 0.20 days; 95%
CI -1.78 to 2.18).
Overall completeness and applicability of
evidence
Unfortunately the evidence base for this important question was
largely incomplete due to the small number of studies with data
relevant to our prespecified criteria and the limited data available
from only one study. As the results are based on data from one
small study the evidence has limited applicability.
Quality of the evidence
Eight studies with at least 185 valve surgery patients were eligible
for inclusion in the review, but most had either low or modest
powerwith the number of valve patients in six studies ranging from
one to 28 (Chen 2002; Chen 2004; Efstathiou 2003a; Hachida
1995; Hurst 1997; Leal-Noval 2005). Another study did not re-
port the number of valve surgery patients (Palanzo 1993a) and
one study included 94 patients (Soo 2010). However, only one
study with 24 participants contributed data to the analysis of two
of the review outcomes. The risk of bias in the included studies
was generally unclear, except for one study where risk of bias was
generally low (Soo 2010). Reporting standards in the majority of
studies were not consistent with CONSORT criteria for reporting
of RCTs.
We were disappointed that data for valve surgery patients were
not available from studies that had measured our predefined out-
comes. We were also concerned that two of our primary and five
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of our secondary outcomes were not measured in any of the eight
included studies. We will address this further in the section ’Im-
plications for research’.
Potential biases in the review process
In order to reduce bias, a comprehensive and systematic search of
the published and unpublished literature was conducted for po-
tentially relevant studies. Where valve surgery patients were part
of a mixed surgery population we contacted the authors for infor-
mation on the valve surgery patients alone, but none was made
available. The search results were examined by two independent
authors in order to minimise bias in the selection process. We were
unable to assess publication bias as too few trials contributed data
to the review.
Agreements and disagreements with other
studies or reviews
There are no other Cochrane reviews on leukodepletion for car-
diac surgery. A number of reviews have examined the role of
leukodepletion in cardiac surgery, largely recommending further
high quality RCTs, but most have been in the context of coro-
nary artery bypass graft (CABG) surgery (Asimakopoulos 2003;
Boodram 2008; Matheis 2001a; Warren 2007a; Warren 2007b;
Warren 2008; Whitaker 2001). However, a review by Loberg and
colleagues considered that there was sufficient evidence to recom-
mend that leukodepletion should not be used routinely in patients
undergoing CABG surgery (Loberg 2011). Only one review in-
cluded a subgroup analysis of valve surgery patients (Lim 2007),
concluding that there was limited positive evidence of biochem-
ical improvements but too few studies to draw firm conclusions
with regard to clinical outcomes. This is consistent with the results
of our review showing that the evidence base is limited by study
composition, quality and size.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are currently insufficient good quality trials that compare
arterial line leukodepletion with standard arterial line filters in
valve surgery patients to inform recommendations for changes in
practice.
Implications for research
Future studies on arterial line leukodepletion in patients under-
going elective heart valve surgery should consider the following.
• The conduct of cardiopulmonary bypass ought to be
standardized, where practicable, to eliminate potential
confounding variables. This could be achieved for the majority
of patients presenting for heart valve surgery.
• Inclusion of key clinical outcomes such as mortality,
markers of renal impairment, health-related quality of life,
adverse events and costs of care
• The potential renoprotective benefit of leukodepletion
would logically be best assessed in those with preserved left
ventricular (LV) function (ejection fraction (EF) > 40%) in the
first instance as poor LV function is an established independent
predictor of post-operative renal dysfunction in this setting.
A future NIHR-funded feasibility study of leukodepletion versus
a standard arterial line filter for patients undergoing elective heart
valve surgery, led by Mr Augustine Tang, is due to begin in Spring
2013 (the ROLO trial). The study design conforms to interna-
tional best practice for trial design and will measure most of the
outcomes specified in this review. It aims to recruit 108 patients
over 18 months. Once complete it will make a significant contri-
bution to this review, being the largest study to date. The ROLO
study is designed to inform parameterisation of a larger multi-
centre randomised controlled trial.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chen 2002
Methods Randomised controlled trial. Number of centres and blinding not stated
Participants 24 adult patients undergoing coronary artery bypass grafting (CABG), heart valve re-
placement, or repair of a congenital heart defect randomised (leukodepletion filter (LD)
12, control filter 12)
Baseline characteristics:mean age 60 years, 88%male, 21 CABG, 2 valve replacement,
1 congenital heart defect
Inclusion: not stated
Exclusion: infection, reoperation, emergency operation
Interventions Same standard anaesthesia and CPB regimens used in both groups. Median sternotomy,
300 units/kg sodium heparin intravenously prior to CPB using a disposable membrane
oxygenator. Moderate systemic hypothermia
Leukodepletion: Pall LG6 arterial line filter
Control: standard arterial line filter (no detail)
Outcomes Intra-operative: CPB time
Total white blood cell count (WBC) 103/mm3, neutrophil counts of CD11a, CD11b,
CD11c and L-selectin
Blood samples collected from at 7 time points: 1. after anaesthesia before sternotomy, 2-
4. After 10, 30, 60 minutes of CPB, 5. conclusion of CPB, 6. 5 mins after administration
of protamine, 7. 2 hours after cessation of CPB
Notes First author emailed requesting outcome data for valve patients alone
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all patients
Selective reporting (reporting bias) Low risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
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Chen 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Chen 2004
Methods Randomised controlled trial. Number of centres and blinding not stated
Participants 32 consecutive adult patients undergoing coronary artery bypass grafting (CABG) or
heart valve operation (leukodepletion filter (LD) 16, control filter 16)
Baseline characteristics: mean age 61 years, 81% male, 31 CABG, 1 valve replacement
Inclusion: not stated
Exclusion: prior cardiac operation, infection, emergency operation, congestive heart
failure, acute myocardial infarction in past month, corticosteroid therapy, severe asthma,
COPD
Interventions Identical anaesthetic and monitoring techniques were used in both groups. Median
sternotomy, 300 units/kg sodium heparin intravenously prior to CPB using a disposable
membrane oxygenator. Uncoated extracorporeal circuit.Moderate systemic hypothermia
Leukodepletion: Pall LG6 arterial line filter
Control: standard arterial line filter (no detail)
Outcomes Intra-operative: CPB time
Total white blood cell count (WBC) 103/mm3, neutrophil count, plasma concentrations
of P-selectin, ICAM-1, IL-8, PECAM-1, oxygen index (before and after CPB), duration
of post-operative intubation and mediastinal drainage (cumulative after 24hrs in ICU)
Blood samples collected at 7 time points: 1. after anaesthesia before sternotomy, 2-3.
After 30 and 60minutes of CPB, 4. fiveminutes after coronary reperfusion, 5. conclusion
of CPB, 6-7. two and 24 hours after cessation of CPB
Notes No valve patients in the control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all patients
Selective reporting (reporting bias) Low risk All collected data reported
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Chen 2004 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Efstathiou 2003a
Methods Randomised controlled trial. Number of centres and blinding not stated
Participants Sept 1999-Mar 2000 80 adult patients electively undergoing coronary artery bypass
grafting (CABG) or heart valve replacement or both (leukodepletion filter (LD) 40,
control filter 40)
Baseline characteristics:mean age 61 years, 74%male, 65CABG, 11 valve replacement,
3 both. EF<30% 5 pts, EF 30-50% 25 pts, EF>50% 37 pts
Inclusion: not stated
Exclusion: chronic renal failure, chronic pulmonary disease, malignancies and reopera-
tion. Acetylsalicylic acid discontinued 8 days before operation
Interventions Identical monitoring techniques were used in both groups. Median sternotomy, 300
units/kg sodium heparin prior to CPB using a membrane oxygenator primed with apro-
tinin. Moderate systemic hypothermia. After CPB all residual blood from the CPB ma-
chine was reinfused via the relevant arterial line filters in each group
Leukodepletion: Pall LG6 arterial line filter
Control: standard Pall arterial line filter
Outcomes Intra-operative: CPB time
White blood cell count (WBC) 109/L and platelet counts pre-operatively, 2, 18, 42 and
66 hours after CPB, mean adrenaline dose in first 12 hours and catecholamine dose,
oxygenation index every 2 hours for 14 hours, ventilation time (hours), ICU stay (hours),
chest tube drainage (ml/24hrs), units packed red cells, urine output (ml/24hrs), hospital
stay (days), number of pts with: wound infection, perioperative infarction, pulmonary
atelectasis, arrhythmias, AF, VF or VT
Notes First author emailed requesting outcome data for valve patients alone
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Efstathiou 2003a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data reported for all patients
Selective reporting (reporting bias) Unclear risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Hachida 1995
Methods Randomised controlled trial. Number of centres and blinding not stated
Participants 28 adult patients undergoing open heart valvular surgery (leukodepletion filter (LD) 14,
control filter 14)
Baseline characteristics: mean age 54 years, gender not stated, all valve surgery, no dif-
ference in pre-operative variables (body surface area, type of cardiac disease, haemoglobin
and neutrophil count). Mean pre-operative fractional shortening <30% in both groups
Inclusion: not stated
Exclusion: abnormal pre-operative lung function (pre-op arterial blood gases, chest x-
ray and pulmonary function)
Interventions All patients on same CPB circuit (no detail) except for filter. Systemic cooling to 28°C
Leukodepletion: Pall LG6 arterial line filter after aortic declamp
Control: Pall Auto Vent-SV filter
Outcomes Intra-operative: aortic cross-clamp time, CPB time
White blood cell count (WBC), CK-MB and lipid peroxide; pre-op, in first hour (5/
15/30/45/60/pump off (min), 3, 6, 12 and 24 hrs after reperfusion. Cardiac index
and percent fraction shortening pre- and post-op. Catecholamine dose after surgery.
Pulmonary index pre-op, 3, 6, 12 and 24 hours after reperfusion. Chest tube drainage,
blood product usage, post-operative chest x-rays. Post-operative infections
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Hachida 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients per outcome or with-
drawal and completion rates not reported
Selective reporting (reporting bias) Low risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Hurst 1997
Methods Randomised controlled trial. Single centre, investigators blinded to intervention
Participants July 1993-Jun 1994 24 adult patients electively undergoing open heart valve surgery
(leukodepletion filter (LD) 11, control filter 13)
Baseline characteristics: mean age 62 years, 46% male, all valve surgery. EF<50% 9
pts, 13 pts cough, 11 pts past smoker, 22 pts dyspnoea grade 1-4
Inclusion: not stated
Exclusion: informed consent unobtainable, emergency surgery
Interventions All patients followed to discharge. Surgery and anaesthesia according to usual practice
of 2 participating surgeons. Systemic cooling to 24-28°C. No CPB details
Leukodepletion: Pall LG6 arterial line filter
Control: Pall Autovent SP filter
Outcomes Intra-operative: aortic cross-clamp time, CPB time, fluid balance, mediastinal blood loss
Haemodynamics and blood samples, pre-op, after anaesthetic induction, at aortic x-
clamp, 1/4/24 hrs post-op. systemic arterial pressure, right arterial pressure, pulmonary
artery pressure, pulmonary capillary wedge pressure, cardiac index, blood gases, oxy-
gen saturation, WBC count, neutrophil count, platelet count, IL-6SR, CD11b, CD18.
Weight, chest x-ray, fluid balance, FEV1 & FVC on 2nd and 5th post-op day and dis-
charge. Echocardiography, fractional shortening, ejection fraction, wall motion abnor-
malities and atelectasis measured pre-op and on discharge. Number of MIs
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Hurst 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients per outcome or with-
drawal and completion rates not reported
Selective reporting (reporting bias) Unclear risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators blinded to intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Some outcome assessments blinded (atelec-
tasis and wall motion)
Leal-Noval 2005
Methods Randomised controlled trial. Single centre. Stratified by risk (Parsonnet score)
Participants June 2003-Dec 2003 162 adult patients electively undergoing cardiac surgery (leukode-
pletion filter (LD) 54, control filter 108)
Baseline characteristics: mean age 61 years, 62% male, 57 CABG, 94 valve surgery, 8
congenital defect. Mean Parsonnet score 6 EF<50% 9 pts
Inclusion: Low risk (Parsonnet score ≤ 10)
Exclusion: urgent surgery, high risk (Parsonnet score > 10), abnormal pre-operative pul-
monary function (COPD, severe pulmonary hypertension), severe pre-operative cardiac
dysfunction (EF <40%, left main coronary artery disease, intra-aortic balloon pump
prior to surgery), pre-operative anaemia (haemoglobin <110 g/L), haemostatic dysfunc-
tion (platelet count <200x109 , thrombin or partial thromboplastin time >1.5 control),
fever or infection symptoms before surgery
Interventions Stratified into 3 groups by Parsonnet score (low<4, middle 4-7, high 8-10) then within-
strata 2:1 ratio randomisation into control or filter group. Perfusion and CPB using a
disposable membrane oxygenator (primed with aprotinin for valve patients) were the
same for all patients except for the arterial line filter. Filtration at start of CPB until end
of procedure. Systemic cooling to 31°C
Leukodepletion: Pall LG6 arterial line filter
Control: standard arterial line filter (no details)
Outcomes Intra-operative: aortic cross-clamp time, CPB time
Morbidity using surrogate variables (length of stay in ICU, pulmonary function (intra-
op, after 1 and4hrs in ICU), cardiac function (perioperative ischemia, EF, cardiac output,
post-op heart failure, cardiac enzymes (highest in 24 hrs), incidence of peri-operative
infections (pneumonia, mediastinitis, sepsis), fever and hyperdynamic circulatory states.
Leucocyte and platelet counts, and haemoglobin levelsmeasured pre-op, aortic de-clamp,
conclusion of CPB, after 1 and 12 hrs in ICU
Notes
Risk of bias
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Leal-Noval 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 2:1 ratio block (block size not reported)
randomisation
Allocation concealment (selection bias) Low risk Sequentially numbered identical contain-
ers
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 pts withdrew from LD group and 1 with-
drew from control group, reasons not re-
ported. All outcome data reported per pro-
tocol
Selective reporting (reporting bias) Unclear risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Abstract states ’blind’ study but not de-
scribed or mentioned in main text
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Palanzo 1993a
Methods Randomised controlled trial. Number of centres and blinding not stated
Participants 36 adult patients electively undergoing open heart surgery for coronary artery disease or
aortic valvular disease (leukodepletion filter (LD) 18, control filter 18)
Baseline characteristics:mean age 64 years, gender not stated, number of valve patients
not stated
Inclusion: normal pre-operative lung function (pre-op arterial blood gases, chest x-rays,
pulmonary function)
Exclusion: abnormal pre-operative lung function (as above), EF not reported
Interventions All patients on same CPB circuit (no detail) except for filter. Systemic cooling to 28°C
Leukodepletion: Pall LG6 arterial line filter
Control: Pall EC-Plus filter
Outcomes Intra-operative: aortic cross-clamp time, CPB time, urine output, blood and blood prod-
ucts used
White blood cell counts (103/mm3) including elastase concentrations (µg/L) measured
pre-op, immediately post-op, 4 and 24 hrs post-op, platelet measured as % drop from
pre-op to immediately post-op and 4 hrs post-op, haemoglobin (g/dl) measured pre-op,
post-bypass, immediately post-op, 4 and 24 hrs post-op, urine output (L/24hrs), chest
tube drainage (ml/24 hrs), blood usage (units/1st 24 hrs), chest x-rays, arterial blood gases
(pCO2 and pO2 (mmHg) measured pre-op, post-bypass and post-extubation, ventilator
(hrs), ICU (hrs), systemic and pulmonary vascular resistance, 1st 24 hr post-op body
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Palanzo 1993a (Continued)
temperature
Notes First author emailed requesting outcome data for valve patients alone. Author replied
that data are no longer available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of patients per outcome or with-
drawal and completion rates not reported
Selective reporting (reporting bias) Low risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Soo 2010
Methods Randomised controlled trial. Single centre. Blinded investigators
Participants 40 adult patients undergoing elective CABG or valvular heart surgery (leukodepletion
filter (LD) 20, control filter 20)
Baseline characteristics: mean age 62 years, 73% male, 18 CABG, 19 valve, 3 both,
EF good/moderate/poor (no definition)
Inclusion: not stated
Exclusion: active infection, emergency operation, pre-operative corticosteroid therapy,
severe asthma or COPD
Interventions Similar anaesthetic and monitoring techniques were used in both groups. Median ster-
notomy, 300 units/kg sodium heparin intravenously prior to CPB using a membrane
oxygenator primed with crystalloid solution. Mild hypothermia, 32°C
Leukodepletion: Pall LG6 arterial line filter
Control: standard arterial line filter (no detail)
Outcomes Intra-operative: CPB time, aortic cross-clamp time
Bloods measured pre-op (within 12 hrs of op), 5 mins after x-clamp release. Total
white blood cell count (WBC) (x109), % neutrophil (x109), neutrophil surface adhe-
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Soo 2010 (Continued)
sion molecule expression: CD11b, CD62L, PSGL-1. Time to extubation (hrs), dura-
tion of postoperative ventilation (hrs), respiratory index (PaO2/FiO2) before extubation
(mmHg), total mediastinal chest drainage (ml) cumulatively after 24 hrs in ICU, cardiac
function (CKMB-fraction (after 24 hrs in ICU), amount and duration of inotropic sup-
port (hrs), cumulative adrenaline usage (µg/kg/hr), duration of adrenaline usage (hrs),
cumulative noradrenaline usage (µg/kg/hr), duration of noradrenaline usage (hrs), high-
est lactate level (median), max change in serum creatinine (ratio of max post-op to pre-
op), ICU stay (hrs)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Randomisation was achieved with sealed
envelopes given to the perfusion depart-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete patient numbers reported for all
outcomes indicate no study withdrawal
Selective reporting (reporting bias) Low risk All collected data reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk A record of the filter used for each patient
was kept by the perfusion staff. This record
was revealed only during data analysis. All
other investigators were blinded to the pa-
tient allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bilgin 2002 Did not meet inclusion criteria. Blood transfusion, no filter on arterial line of cardiopulmonary bypass
Dell’Amore 2010 Not an arterial line filter. Residual blood
El-Tahan 2009 Did not meet inclusion criteria. Ultrafiltration, no filter on arterial line of cardiopulmonary bypass
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(Continued)
Gott 1998 Did not meet inclusion criteria. Not solely arterial line leukodepletion; also leukodepleted cardioplegia,
salvaged and post-operative blood products
Gu 1999a Did not meet inclusion criteria. Filter on venous line of cardiopulmonary bypass
Hamada 2001 Did not meet inclusion criteria. Patients for coronary artery bypass graft
Johnson 1995 Did not meet inclusion criteria. Patients for coronary artery bypass graft
Karaiskos 2004 Not an RCT and did not meet exclusion criteria: mean ejection fraction; filter = 27%, control = 31%
Komai 1998 Did not meet inclusion criteria. Patients for ventricular septal defect
Lust 1996 Did not meet exclusion criteria. Patients for coronary artery bypass graft
Matheis 2001b Did not meet inclusion criteria. Patients for coronary artery bypass graft
Onorati 2011 Did not meet inclusion criteria. Not solely arterial line leukodepletion; also leukodepleted cardioplegia
Pala 1995 Did not meet inclusion criteria. Leukodepletion on cardioplegia circuit only
Scholz 2002 Did not meet inclusion criteria. Patients for coronary artery bypass graft
Smit 1999 Did not meet inclusion criteria. Filter on venous line of cardiopulmonary bypass
Soo 2008 Did not meet inclusion criteria. In vitro study (see Soo 2010)
Soo 2009 Did not meet inclusion criteria. In vitro study (see Soo 2010)
van de Watering 1996 Did not meet inclusion criteria. Blood transfusion, no filter on arterial line of cardiopulmonary bypass
Zhang 2005 Did not meet inclusion criteria. No leukocyte depletion filter
Characteristics of studies awaiting assessment [ordered by study ID]
Allen 1994
Methods RCT
Participants 50 patients (26 LD, 24 standard filter). No detail on age, specific surgery or gender
Interventions Anaesthesia, operation and CPB standardised. Pall LG6 arterial line filter versus Pall EC Plus arterial line filter.
Systemic hypothermia to 28°C
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Allen 1994 (Continued)
Outcomes Total and differential white blood cell counts measured 8 times from before start of CPB to 24 hours after CPB (pre-
op, start CPB, 15mins into CPB, 30mins into CPB, 5 mins after cross-clamp removal, CPB+5mins, CPB+30mins,
CPB+120mins, 24 hours after end of CPB) Pulmonary function: alveolar arterial oxygen gradients, compliance,
clinical morbidity scale
Notes Conference abstract. Unclear whether valve patients. First author emailed for further information
de Vries 2003
Methods RCT
Participants 40 adult patients (25 male), aged 65, undergoing CABG or valve surgery (7 relevant valve)
Interventions Grp 1: Pall LG6 arterial line filter,Grp 2: Pall RS1 paired leucocyte removal filters on venous return during rewarming,
Grp3: Pall RS1 leucofiltration of residual heart-lungmachine blood at transfusion after CPB, Grp4: No leucofiltration
controls
Outcomes Blood cell counts, arterial oxygen tension and alveolar-arterial oxygen gradient, plasma elastase, perioperative fluid
balance, use of inotropic agents, myocardial infarctions, duration of postoperative intubation, length of stay in ICU
and hospital
Notes Unclear whether control group included standard arterial line filters as authors state “Arterial line filters other than the
one studied were not used”. First author emailed for clarification
Koskenkari 2006
Methods RCT
Participants 20 adults patients (17 male), aged 70 years, undergoing valve replacement with coronary revascularisation. 10 LD
and 10 control group
Interventions Pall LG6 arterial line filter versus control group. Moderate systemic hypothermia 34°C
Outcomes ICU stay, surgical ward stay, intubation time, arterial saturation, blood transfusion, platelet transfusion, inotropic
and vasopressor support, myocardial infarction, blood cell counts, cytokine analysis
Notes Unclear whether control group included standard arterial line filter as authors state LG6 used in intervention group
but CPB in control conducted “without such a filter”. Sixth author emailed for further information
Ohto 2000
Methods Unclear. “Twenty-six adults operated for valvular heart disease were included in this study”
Participants 26 adults (12 male), aged 56, undergoing valve surgery. 13 LD and 13 control
Interventions Pall LG6 arterial line leucodepletion filter verus Pall Auto Vent-SV standard arterial line filter
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Ohto 2000 (Continued)
Outcomes Blood cell counts, elastase and lipoperoxide concentrations and oxygenation index, blood transfusions
Notes Unclear whether patients were randomised to the two arms. Second author emailed for further information
Zhang 2010
Methods RCT
Participants 52 adult patients (20 male) aged 43 years, undergoing valve surgery. 26 LD and 26 standard filter
Interventions Pall LG6 arterial line filter versus control group. Moderate systemic hypothermia 25-28°C
Outcomes Blood cell counts, creatinine kinase, troponin I, oxygen index, inotropic support, duration of mechanical ventilation,
length of ICU stay and length of hospital stay
Notes Unclear whether control group included standard arterial line filter as authors state that the control group “received
the same CPB circuit as the filter group but without the leucocyte filter.” Last author emailed for further information
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D A T A A N D A N A L Y S E S
Comparison 1. Leukodepletion versus standard filter




participants Statistical method Effect size
1 Length of hospital stay 1 24 Mean Difference (IV, Fixed, 95% CI) 0.20 [-1.78, 2.18]
2 Length of stay ICU 1 24 Mean Difference (IV, Fixed, 95% CI) 0.8 [-0.24, 1.84]
Analysis 1.1. Comparison 1 Leukodepletion versus standard filter, Outcome 1 Length of hospital stay.
Review: Leukodepletion for patients undergoing heart valve surgery
Comparison: 1 Leukodepletion versus standard filter
Outcome: 1 Length of hospital stay





N Mean(SD)[Days] N Mean(SD)[Days] IV,Fixed,95% CI IV,Fixed,95% CI
Hurst 1997 11 8.5 (2.6) 13 8.3 (2.3) 100.0 % 0.20 [ -1.78, 2.18 ]
Total (95% CI) 11 13 100.0 % 0.20 [ -1.78, 2.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Leukodepletion Favours Standard
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Analysis 1.2. Comparison 1 Leukodepletion versus standard filter, Outcome 2 Length of stay ICU.
Review: Leukodepletion for patients undergoing heart valve surgery
Comparison: 1 Leukodepletion versus standard filter
Outcome: 2 Length of stay ICU





N Mean(SD)[Days] N Mean(SD)[Days] IV,Fixed,95% CI IV,Fixed,95% CI
Hurst 1997 11 2.5 (1.7) 13 1.7 (0.5) 100.0 % 0.80 [ -0.24, 1.84 ]
Total (95% CI) 11 13 100.0 % 0.80 [ -0.24, 1.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Leukodepletion Favours Standard
A P P E N D I C E S
Appendix 1. Search strategies - RCTs
CENTRAL
#1MeSH descriptor Leukocytes explode all trees
#2MeSH descriptor Leukocyte Reduction Procedures, this term only






#9(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10MeSH descriptor Heart Valve Diseases explode all trees
#11MeSH descriptor Heart Valve Prosthesis explode all trees
#12MeSH descriptor Heart Valve Prosthesis Implantation explode all trees
#13 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) near/3 valv*)
#14((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 prosthes?s)
#15((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 incompetenc*)
#16((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 regurgitation*)
#17((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 insufficienc*)
#18((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 stenos?s)
#19((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 surg*)
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#20((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 replace*)
#21 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 repair*)
#22((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 reconstruc*)
#23((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 operat*)












10. exp Heart Valve Diseases/
11. Heart Valve Prosthesis/
12. Heart Valve Prosthesis Implantation/
13. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) adj3 valv*).tw.
14. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj3 (prosthes?s or incompetenc* or regurgitation* or
insufficienc* or stenos?s)).tw.
15. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj4 (surg* or replace* or repair* or reconstruc* or
operat*)).tw.
16. or/10-15
17. 9 and 16
18. randomized controlled trial.pt.







26. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27. exp animals/ not humans.sh.
28. 26 not 27
29. 17 and 28
EMBASE Ovid
1 exp leukocytes/








10 exp Heart Valve Diseases/
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11 Heart Valve Prosthesis/
12 Heart Valve Prosthesis Implantation/
13 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) adj3 valv*).tw.
14 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj3 (prosthes?s or incompetenc* or regurgitation* or
insufficienc* or stenos?s)).tw.
15 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj4 (surg* or replace* or repair* or reconstruc* or
operat*)).tw.
16 or/10-15







24 (doubl$ adj blind$).tw.





30 double blind procedure/
31 randomized controlled trial/
32 single blind procedure/
33 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34 (animal/ or nonhuman/) not human/
35 33 not 34
36 17 and 35
Web of Science
# 21 #20 AND #19
# 20 Topic=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
# 19 #18 AND #6
# 18 #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7
# 17 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 operat*))
# 16 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 reconstruc*))
# 15 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 repair*))
# 14 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 replace*))
# 13 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/4 surg*))
# 12 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 stenos?s))
# 11 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 insufficienc*))
# 10 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 regurgitation*))
# 9 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 incompetenc*))
# 8 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) near/3 prosthes?s))
# 7 Topic=(((heart or cardiac or aortic or mitral or pulmonary or tricuspid) near/3 valv*))
# 6 #5 OR #4 OR #3 OR #2 OR #1
# 5 Topic=(neutrophil*)
# 4 Topic=(wbc)
# 3 Topic=(“white blood cell*”)
# 2 Topic=(leu?ocyt*)
# 1 Topic=(leu?odeplet*)
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CINAHL
1. exp leukocytes/ in CINAHL Headings
2. “Leukocyte Reduction Procedures” as keyword
3. Filtration/ in CINAHL Headings
4. leu?odeplet* as keyword
5. leu?ocyt* as keyword
6. “white blood cell*” as keyword
7. wbc.tw. as keyword
8. neutrophil* as keyword
9. or/1-8
10. exp Heart Valve Diseases/ in CINAHL Headings
11. Heart Valve Prosthesis/ in CINAHL Headings
12. Heart Valve Prosthesis Implantation/ in CINAHL Headings
13. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) N3 valv*) as keyword
14. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) N3 (prosthes?s or incompetenc* or regurgitation* or
insufficienc* or stenos?s)) as keyword
15. ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) N4 (surg* or replace* or repair* or reconstruc* or operat*))
as keyword
16. or/10-15
17. 9 and 16
18. randomized controlled trial Publication Type
19. “controlled clinical trial” Abstract
20. randomized Abstract
21. placebo Abstract
22. “drug therapy” as keyword
23. randomly as keyword
24. trial as keyword
25. groups as keyword
26. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27. 17 AND 26
NHS Economics Evaluation Database
ANY FIELD “Leukocyte reduction procedures”
ANY FIELD “Heart valve prosthesis”
ANY FIELD “Heart valve prosthesis implementation”
MeSH DESCRIPTOR Leukocyte Reduction Procedures EXPLODE ALL TREES
MeSH DESCRIPTOR Heart Valve Prosthesis EXPLODE ALL TREES
MeSH DESCRIPTOR Heart Valve Prosthesis Implantation EXPLODE ALL TREES
Restrict to NHS EED.
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Appendix 2. Search strategies - adverse events
MEDLINE Ovid
1 exp leukocytes/








10 exp Heart Valve Diseases/
11 Heart Valve Prosthesis/
12 Heart Valve Prosthesis Implantation/
13 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) adj3 valv*).tw.
14 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj3 (prosthes?s or incompetenc* or regurgitation* or
insufficienc* or stenos?s)).tw.
15 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj4 (surg* or replace* or repair* or reconstruc* or
operat*)).tw.
16 or/10-15






23 (toxi* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
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24 (adverse* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
25 (side adj3 (effect or effects)).tw.
26 (adr or adrs).tw.
27 or/18-26
28 exp animals/ not humans.sh.
29 27 not 28
30 17 and 29
EMBASE
1 exp leukocytes/








10 exp Heart Valve Diseases/
11 Heart Valve Prosthesis/
12 Heart Valve Prosthesis Implantation/
13 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid) adj3 valv*).tw.
14 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj3 (prosthes?s or incompetenc* or regurgitation* or
insufficienc* or stenos?s)).tw.
15 ((heart or cardiac or aortic or mitral or pulmonary or tricuspid or valv*) adj4 (surg* or replace* or repair* or reconstruc* or
operat*)).tw.
16 or/10-15





22 (toxi* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
23 (adverse* adj2 (effect or effects or reaction* or event or events or outcome*)).tw.
24 (side adj3 (effect or effects)).tw.
25 (adr or adrs).tw.
26 adverse drug reaction/
27 or/18-26
28 (animal/ or nonhuman/) not human/
29 27 not 28
30 17 and 29
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